Gaurav Shah, Rocket Pharmaceuticals CEO

Ren­o­va­cor ships its car­diac gene ther­a­py to Rock­et in $53M all-stock deal

Ren­o­va­cor want­ed to be in the clin­ic al­ready. The biotech ex­pect­ed an $11 mil­lion Se­ries A in sum­mer 2019 would bankroll an IND fil­ing for its car­diac gene ther­a­py, but as it goes with drug R&D, the path took some twists.

Fifty-four weeks af­ter ship­ping up to New York City for a blank check merg­er, Ren­o­va­cor is turn­ing off the lights on $RCOR and go­ing the way of $RCKT, or Rock­et Phar­ma­ceu­ti­cals, in an all-stock deal that adds to the lat­ter’s gene ther­a­py am­bi­tions, which in­cludes two like­ly BLA fil­ings next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.